{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:34:19Z","timestamp":1787168059912,"version":"build-2736575974"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:00:00Z","timestamp":1365033600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1741-7015-11-95","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T04:54:13Z","timestamp":1365051253000},"source":"Crossref","is-referenced-by-count":96,"title":["Renal involvement in autoimmune connective tissue diseases"],"prefix":"10.1186","volume":"11","author":[{"given":"Andreas","family":"Kronbichler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"714_CR1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00005792-200007000-00005","volume":"79","author":"A Goules","year":"2000","unstructured":"Goules A, Masouridi S, Tzioufas AG, Ioannidis JP, Skopouli FN, Moutsopoulos HM: Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore). 2000, 79: 241-249.","journal-title":"Medicine (Baltimore)"},{"key":"714_CR2","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/ndt\/16.12.2328","volume":"16","author":"N Bossini","year":"2001","unstructured":"Bossini N, Savoldi S, Franceschini F, Mombelloni S, Baronio M, Cavazzana I, Viola BF, Valzorio B, Mazzucchelli C, Cattaneo R, Scolari F, Maiorca R: Clinical and morphological features of kidney involvement in primary Sjogren's syndrome. Nephrol Dial Transplant. 2001, 16: 2328-2336.","journal-title":"Nephrol Dial Transplant"},{"key":"714_CR3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","volume":"100","author":"H Penn","year":"2007","unstructured":"Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP: Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007, 100: 485-494.","journal-title":"QJM"},{"key":"714_CR4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5858\/133.2.233","volume":"133","author":"SV Seshan","year":"2009","unstructured":"Seshan SV, Jennette JC: Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med. 2009, 133: 233-248.","journal-title":"Arch Pathol Lab Med"},{"key":"714_CR5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00460110","volume":"5","author":"RA Sinico","year":"2010","unstructured":"Sinico RA, Cavazzana I, Nuzzo M, Vianelli M, Napodano P, Scaini P, Tincani A: Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol. 2010, 5: 1211-1217.","journal-title":"Clin J Am Soc Nephrol"},{"key":"714_CR6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.00980209","volume":"4","author":"S Maripuri","year":"2009","unstructured":"Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV, Hogan MC: Renal involvement in primary Sjogren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol. 2009, 4: 1423-1431.","journal-title":"Clin J Am Soc Nephrol"},{"key":"714_CR7","first-page":"278","volume":"35","author":"H Ren","year":"2008","unstructured":"Ren H, Wang WM, Chen XN, Zhang W, Pan XX, Wang XL, Lin Y, Zhang S, Chen N: Renal involvement and followup of 130 patients with primary Sjogren's syndrome. J Rheumatol. 2008, 35: 278-284.","journal-title":"J Rheumatol"},{"key":"714_CR8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1523-1747.1998.00073.x","volume":"110","author":"T Kawakami","year":"1998","unstructured":"Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M: Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol. 1998, 110: 47-51.","journal-title":"J Invest Dermatol"},{"key":"714_CR9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1523-1747.ep12318465","volume":"105","author":"A Igarashi","year":"1995","unstructured":"Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, Takehara K: Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol. 1995, 105: 280-284.","journal-title":"J Invest Dermatol"},{"key":"714_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.humpath.2010.05.018","volume":"42","author":"L Mouthon","year":"2011","unstructured":"Mouthon L, Mehrenberger M, Teixeira L, Fakhouri F, Berezne A, Guillevin L, Noel LH: Endothelin-1 expression in scleroderma renal crisis. Hum Pathol. 2011, 42: 95-102.","journal-title":"Hum Pathol"},{"key":"714_CR11","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/anr.1780320911","volume":"32","author":"DJ Helfrich","year":"1989","unstructured":"Helfrich DJ, Banner B, Steen VD, Medsger TA: Normotensive renal failure in systemic sclerosis. Arthritis Rheum. 1989, 32: 1128-1134.","journal-title":"Arthritis Rheum"},{"key":"714_CR12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.2006.066985","volume":"67","author":"L Teixeira","year":"2008","unstructured":"Teixeira L, Mouthon L, Mahr A, Berezne A, Agard C, Mehrenberger M, Noel LH, Trolliet P, Frances C, Cabane J, Guillevin L: Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis. 2008, 67: 110-116.","journal-title":"Ann Rheum Dis"},{"key":"714_CR13","doi-asserted-by":"crossref","first-page":"543704","DOI":"10.1155\/2010\/543704","volume":"2010","author":"I Batal","year":"2010","unstructured":"Batal I, Domsic RT, Medsger TA, Bastacky S: Scleroderma renal crisis: a pathology perspective. Int J Rheumatol. 2010, 2010: 543704.","journal-title":"Int J Rheumatol"},{"key":"714_CR14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1742-1241.2004.00248.x","volume":"59","author":"TH Yen","year":"2005","unstructured":"Yen TH, Lai PC, Chen CC, Hsueh S, Huang JY: Renal involvement in patients with polymyositis and dermatomyositis. Int J Clin Pract. 2005, 59: 188-193.","journal-title":"Int J Clin Pract"},{"key":"714_CR15","first-page":"45","volume":"12","author":"D Joshi","year":"2009","unstructured":"Joshi D, Kumar N, Rai A: Dermatomyositis presenting with rhabdomyolysis and acute renal failure; an uncommon manifestation. Ann Indian Acad Neurol. 2009, 12: 45-47.","journal-title":"Ann Indian Acad Neurol"},{"key":"714_CR16","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","volume":"50","author":"MG Tektonidou","year":"2004","unstructured":"Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM: Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004, 50: 2569-2579.","journal-title":"Arthritis Rheum"},{"key":"714_CR17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.1780380213","volume":"38","author":"HJ Helin","year":"1995","unstructured":"Helin HJ, Korpela MM, Mustonen JT, Pasternack AI: Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 242-247.","journal-title":"Arthritis Rheum"},{"key":"714_CR18","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1053\/j.ajkd.2005.07.019","volume":"46","author":"V Ooms","year":"2005","unstructured":"Ooms V, Decupere M, Lerut E, Vanrenterghem Y, Kuypers DR: Secondary renal amyloidosis due to long-standing tubulointerstitial nephritis in a patient with Sjogren syndrome. Am J Kidney Dis. 2005, 46: e75-e80.","journal-title":"Am J Kidney Dis"},{"key":"714_CR19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1468-3083.2006.01441.x","volume":"20","author":"AM Roguedas","year":"2006","unstructured":"Roguedas AM, Youinou P, Lemasson G, Pennec YL, Misery L: Primary Gougerot-Sjogren syndrome: a dermatological approach. J Eur Acad Dermatol Venereol. 2006, 20: 243-247.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"714_CR20","first-page":"8","volume":"50","author":"R Manthorpe","year":"1997","unstructured":"Manthorpe R, Asmussen K, Oxholm P: Primary Sjogren's syndrome: diagnostic criteria, clinical features, and disease activity. J Rheumatol Suppl. 1997, 50: 8-11.","journal-title":"J Rheumatol Suppl"},{"key":"714_CR21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3349\/ymj.2003.44.6.947","volume":"44","author":"HU Rehman","year":"2003","unstructured":"Rehman HU: Sjogren's syndrome. Yonsei Med J. 2003, 44: 947-954.","journal-title":"Yonsei Med J"},{"key":"714_CR22","volume-title":"Rheumatol Int","author":"H Yilmaz","year":"2012","unstructured":"Yilmaz H, Kaya M, Ozbek M, Ureten K, Safa Yildirim I: Hypokalemic periodic paralysis in Sjogren's syndrome secondary to distal renal tubular acidosis. Rheumatol Int. 2012, Epub ahead of print"},{"key":"714_CR23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5414\/CNP65427","volume":"65","author":"T Kobayashi","year":"2006","unstructured":"Kobayashi T, Muto S, Nemoto J, Miyata Y, Ishiharajima S, Hironaka M, Asano Y, Kusano E: Fanconi's syndrome and distal (type 1) renal tubular acidosis in a patient with primary Sjogren's syndrome with monoclonal gammopathy of undetermined significance. Clin Nephrol. 2006, 65: 427-432.","journal-title":"Clin Nephrol"},{"key":"714_CR24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.kjms.2010.07.003","volume":"27","author":"ML Yang","year":"2011","unstructured":"Yang ML, Kuo MC, Ou TT, Chen HC: Primary Sjogren's syndrome with minimal change disease\u2013a case report. Kaohsiung J Med Sci. 2011, 27: 190-194.","journal-title":"Kaohsiung J Med Sci"},{"key":"714_CR25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/qjmed\/93.5.297","volume":"93","author":"K Aasarod","year":"2000","unstructured":"Aasarod K, Haga HJ, Berg KJ, Hammerstrom J, Jorstad S: Renal involvement in primary Sjogren's syndrome. QJM. 2000, 93: 297-304.","journal-title":"QJM"},{"key":"714_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/kei110","volume":"45","author":"F Pessler","year":"2006","unstructured":"Pessler F, Emery H, Dai L, Wu YM, Monash B, Cron RQ, Pradhan M: The spectrum of renal tubular acidosis in paediatric Sjogren syndrome. Rheumatology (Oxford). 2006, 45: 85-91.","journal-title":"Rheumatology (Oxford)"},{"key":"714_CR27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1600-0625.2010.01082.x","volume":"19","author":"N Hunzelmann","year":"2010","unstructured":"Hunzelmann N, Krieg T: Scleroderma: from pathophysiology to novel therapeutic approaches. Exp Dermatol. 2010, 19: 393-400.","journal-title":"Exp Dermatol"},{"key":"714_CR28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1756-185X.2009.01410.x","volume":"12","author":"G Strange","year":"2009","unstructured":"Strange G, Nash P: The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. Int J Rheum Dis. 2009, 12: 192-206.","journal-title":"Int J Rheum Dis"},{"key":"714_CR29","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007, 66: 754-763.","journal-title":"Ann Rheum Dis"},{"key":"714_CR30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1681\/ASN.2008121226","volume":"21","author":"Y Liu","year":"2010","unstructured":"Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010, 21: 212-222.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/01.bor.0000139310.77347.9c","volume":"16","author":"AE Postlethwaite","year":"2004","unstructured":"Postlethwaite AE, Shigemitsu H, Kanangat S: Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol. 2004, 16: 733-738.","journal-title":"Curr Opin Rheumatol"},{"key":"714_CR32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9343(84)90986-0","volume":"76","author":"VD Steen","year":"1984","unstructured":"Steen VD, Medsger TA, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP: Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984, 76: 779-786.","journal-title":"Am J Med"},{"key":"714_CR33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.30111","volume":"63","author":"B Nguyen","year":"2011","unstructured":"Nguyen B, Mayes MD, Arnett FC, Del Junco D, Reveille JD, Gonzalez EB, Draeger HT, Perry M, Hendiani A, Anand KK, Assassi S: HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum. 2011, 63: 530-534.","journal-title":"Arthritis Rheum"},{"key":"714_CR34","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","volume":"41","author":"VD Steen","year":"1998","unstructured":"Steen VD, Medsger TA: Case\u2013control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998, 41: 1613-1619.","journal-title":"Arthritis Rheum"},{"key":"714_CR35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2010.11.001","volume":"41","author":"U Arad","year":"2011","unstructured":"Arad U, Balbir-Gurman A, Doenyas-Barak K, Amit-Vazina M, Caspi D, Elkayam O: Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum. 2011, 41: 223-229.","journal-title":"Semin Arthritis Rheum"},{"key":"714_CR36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-010-0145-7","volume":"13","author":"G Bussone","year":"2011","unstructured":"Bussone G, Berezne A, Pestre V, Guillevin L, Mouthon L: The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr Rheumatol Rep. 2011, 13: 37-43.","journal-title":"Curr Rheumatol Rep"},{"key":"714_CR37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","volume":"133","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA: Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000, 133: 600-603.","journal-title":"Ann Intern Med"},{"key":"714_CR38","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1111\/j.1600-6143.2005.01035.x","volume":"5","author":"PT Pham","year":"2005","unstructured":"Pham PT, Pham PC, Danovitch GM, Gritsch HA, Singer J, Wallace WD, Hayashi R, Wilkinson AH: Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant. 2005, 5: 2565-2569.","journal-title":"Am J Transplant"},{"key":"714_CR39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/33.1.90","volume":"33","author":"CP Denton","year":"1994","unstructured":"Denton CP, Sweny P, Abdulla A, Black CM: Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol. 1994, 33: 90-92.","journal-title":"Br J Rheumatol"},{"key":"714_CR40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","volume":"1184","author":"AL Mammen","year":"2010","unstructured":"Mammen AL: Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010, 1184: 134-153.","journal-title":"Ann N Y Acad Sci"},{"key":"714_CR41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/BOR.0b013e328333b9e2","volume":"22","author":"JT Clarke","year":"2010","unstructured":"Clarke JT, Werth VP: Rheumatic manifestations of skin disease. Curr Opin Rheumatol. 2010, 22: 78-84.","journal-title":"Curr Opin Rheumatol"},{"key":"714_CR42","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2133.2011.10595.x","volume":"165","author":"CF Kuo","year":"2011","unstructured":"Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, Luo SF: Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol. 2011, 165: 1273-1279.","journal-title":"Br J Dermatol"},{"key":"714_CR43","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar2987","volume":"12","author":"YJ Chen","year":"2010","unstructured":"Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT: Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther. 2010, 12: R70.","journal-title":"Arthritis Res Ther"},{"key":"714_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","volume":"85","author":"D Stockton","year":"2001","unstructured":"Stockton D, Doherty VR, Brewster DH: Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001, 85: 41-45.","journal-title":"Br J Cancer"},{"key":"714_CR45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001, 357: 96-100.","journal-title":"Lancet"},{"key":"714_CR46","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/rheumatology\/32.10.929","volume":"32","author":"NA Frost","year":"1993","unstructured":"Frost NA, Morand EF, Hall CL, Maddison PJ, Bhalla AK: Idiopathic polymyositis complicated by arthritis and mesangial proliferative glomerulonephritis: case report and review of the literature. Br J Rheumatol. 1993, 32: 929-931.","journal-title":"Br J Rheumatol"},{"key":"714_CR47","first-page":"120","volume":"14","author":"OF Valenzuela","year":"2001","unstructured":"Valenzuela OF, Reiser IW, Porush JG: Idiopathic polymyositis and glomerulonephritis. J Nephrol. 2001, 14: 120-124.","journal-title":"J Nephrol"},{"key":"714_CR48","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s10067-006-0200-y","volume":"26","author":"Y Takizawa","year":"2007","unstructured":"Takizawa Y, Kanda H, Sato K, Kawahata K, Yamaguchi A, Uozaki H, Shimizu J, Tsuji S, Misaki Y, Yamamoto K: Polymyositis associated with focal mesangial proliferative glomerulonephritis with depositions of immune complexes. Clin Rheumatol. 2007, 26: 792-796.","journal-title":"Clin Rheumatol"},{"key":"714_CR49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00296-009-1003-7","volume":"30","author":"Q Xie","year":"2010","unstructured":"Xie Q, Liu Y, Liu G, Yang N, Yin G: Diffuse proliferative glomerulonephritis associated with dermatomyositis with nephrotic syndrome. Rheumatol Int. 2010, 30: 821-825.","journal-title":"Rheumatol Int"},{"key":"714_CR50","first-page":"336","volume":"6","author":"RF Dyck","year":"1979","unstructured":"Dyck RF, Katz A, Gordon DA, Johnson M, Shainhouse Z, Cardella CJ, Bear RA: Glomerulonephritis associated with polymyositis. J Rheumatol. 1979, 6: 336-344.","journal-title":"J Rheumatol"},{"key":"714_CR51","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/archinte.1977.03630190089023","volume":"137","author":"H Carleton","year":"1977","unstructured":"Carleton H, Pitts W, Davidson W, Roth P: Muscle disease associated with renal failure. Arch Intern Med. 1977, 137: 939-941.","journal-title":"Arch Intern Med"},{"key":"714_CR52","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(75)91990-X","volume":"1","author":"H Moutsopoulos","year":"1975","unstructured":"Moutsopoulos H, Fye KH: Letter: Lipoid nephrosis and focal glomerulosclerosis in a patient with polymyositis. Lancet. 1975, 1: 1039.","journal-title":"Lancet"},{"key":"714_CR53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2169\/naika.80.108","volume":"80","author":"I Hara","year":"1991","unstructured":"Hara I, Kurata N, Hyozu K, Tamao H: A case of polymyositis complicated with membranous nephritis. Nippon Naika Gakkai Zasshi. 1991, 80: 108-109.","journal-title":"Nippon Naika Gakkai Zasshi"},{"key":"714_CR54","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1159\/000187383","volume":"64","author":"M Tsunemi","year":"1993","unstructured":"Tsunemi M, Ishimura E, Tsumura K, Shoji S, Sugimura T, Nishizawa Y, Morii H: A case of crescentic glomerulonephritis associated with polymyositis. Nephron. 1993, 64: 488-489.","journal-title":"Nephron"},{"key":"714_CR55","first-page":"523","volume":"18","author":"H Fukui","year":"1976","unstructured":"Fukui H, Kimura T, Nakabayashi K, Nagasawa T: Dermatomyositis associated with immune-complex type nephritis induced by tubular epithelial antigen. Nihon Jinzo Gakkai Shi. 1976, 18: 523-533.","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"714_CR56","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2169\/naika.78.994","volume":"78","author":"T Moriyama","year":"1989","unstructured":"Moriyama T, Uruta Y, Yamaguchi H, Fukuzaki M, Uchida Y, Yasumoto Y, Yamashita W, Harada R, Ohsaki K, Nakajima A: A case of immune-complex type glomerulonephritis associated with dermatomyositis. Nippon Naika Gakkai Zasshi. 1989, 78: 994-995.","journal-title":"Nippon Naika Gakkai Zasshi"},{"key":"714_CR57","first-page":"1377","volume":"21","author":"H Makino","year":"1994","unstructured":"Makino H, Hirata K, Matsuda M, Amano T, Ota Z: Membranous nephropathy developing during the course of dermatomyositis. J Rheumatol. 1994, 21: 1377-1378.","journal-title":"J Rheumatol"},{"key":"714_CR58","first-page":"148","volume":"16","author":"TH Yen","year":"2003","unstructured":"Yen TH, Huang JY, Chen CY: Unexpected IgA nephropathy during the treatment of a young woman with idiopathic dermatomyositis: case report and review of the literature. J Nephrol. 2003, 16: 148-153.","journal-title":"J Nephrol"},{"key":"714_CR59","first-page":"801","volume":"32","author":"K Kamata","year":"1982","unstructured":"Kamata K, Kobayashi Y, Shigematsu H, Saito T: Childhood type polymyositis and rapidly progressive glomerulonephritis. Acta Pathol Jpn. 1982, 32: 801-806.","journal-title":"Acta Pathol Jpn"},{"key":"714_CR60","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC: Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725.","journal-title":"Arthritis Rheum"},{"key":"714_CR61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","volume":"82","author":"R Cervera","year":"2003","unstructured":"Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernandez-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003, 82: 299-308.","journal-title":"Medicine (Baltimore)"},{"key":"714_CR62","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2005.11.034","volume":"119","author":"A Doria","year":"2006","unstructured":"Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, Atzeni F, Piccoli A, Todesco S: Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006, 119: 700-706.","journal-title":"Am J Med"},{"key":"714_CR63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","volume":"39","author":"GJ Pons-Estel","year":"2010","unstructured":"Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS: Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010, 39: 257-268.","journal-title":"Semin Arthritis Rheum"},{"key":"714_CR64","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.autrev.2010.02.008","volume":"9","author":"AV Rubtsov","year":"2010","unstructured":"Rubtsov AV, Rubtsova K, Kappler JW, Marrack P: Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev. 2010, 9: 494-498.","journal-title":"Autoimmun Rev"},{"key":"714_CR65","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/rheumatology\/keq214","volume":"49","author":"GS Cooper","year":"2010","unstructured":"Cooper GS, Wither J, Bernatsky S, Claudio JO, Clarke A, Rioux JD, Fortin PR: Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford). 2010, 49: 2172-2180.","journal-title":"Rheumatology (Oxford)"},{"key":"714_CR66","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/art.23626","volume":"58","author":"CC van Bavel","year":"2008","unstructured":"van Bavel CC, Fenton KA, Rekvig OP, van der Vlag J, Berden JH: Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 2008, 58: 1892-1899.","journal-title":"Arthritis Rheum"},{"key":"714_CR67","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1191\/0961203302lu307rr","volume":"11","author":"JW Dieker","year":"2002","unstructured":"Dieker JW, van der Vlag J, Berden JH: Triggers for anti-chromatin autoantibody production in SLE. Lupus. 2002, 11: 856-864.","journal-title":"Lupus"},{"key":"714_CR68","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1681\/ASN.2010050515","volume":"22","author":"M Espeli","year":"2011","unstructured":"Espeli M, Bokers S, Giannico G, Dickinson HA, Bardsley V, Fogo AB, Smith KG: Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol. 2011, 22: 296-305.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jcp.53.6.424","volume":"53","author":"W Egner","year":"2000","unstructured":"Egner W: The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000, 53: 424-432.","journal-title":"J Clin Pathol"},{"key":"714_CR70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0961203309346508","volume":"19","author":"R Aggarwal","year":"2010","unstructured":"Aggarwal R, Sestak AL, D'Sousa A, Dillon SP, Namjou B, Scofield RH: Complete complement deficiency in a large cohort of familial systemic lupus erythematosus. Lupus. 2010, 19: 52-57.","journal-title":"Lupus"},{"key":"714_CR71","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00296-011-1962-3","volume":"32","author":"H Julkunen","year":"2012","unstructured":"Julkunen H, Ekblom-Kullberg S, Miettinen A: Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol Int. 2012, 32: 2445-2451.","journal-title":"Rheumatol Int"},{"key":"714_CR72","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A, Ferrario F, Floege J, Houssiau F, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C: Joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012, 71: 1771-1782.","journal-title":"Ann Rheum Dis"},{"key":"714_CR73","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","volume":"19","author":"DJ Birmingham","year":"2010","unstructured":"Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, Yu CY, Hebert LA, Rovin BH: The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010, 19: 1272-1280.","journal-title":"Lupus"},{"key":"714_CR74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10067-003-0724-3","volume":"22","author":"P Oelzner","year":"2003","unstructured":"Oelzner P, Deliyska B, Funfstuck R, Hein G, Herrmann D, Stein G: Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement. Clin Rheumatol. 2003, 22: 271-278.","journal-title":"Clin Rheumatol"},{"key":"714_CR75","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1177\/0961203311411597","volume":"20","author":"E Akhter","year":"2011","unstructured":"Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M: Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011, 20: 1267-1274.","journal-title":"Lupus"},{"key":"714_CR76","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/art.30401","volume":"63","author":"Y Katsumata","year":"2011","unstructured":"Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T, Baba S, Hara M, Yamanaka H: Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum. 2011, 63: 2436-2444.","journal-title":"Arthritis Rheum"},{"key":"714_CR77","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/0961203306070002","volume":"15","author":"ME Zabaleta-Lanz","year":"2006","unstructured":"Zabaleta-Lanz ME, Munoz LE, Tapanes FJ, Vargas-Arenas RE, Daboin I, Barrios Y, Pinto JA, Bianco NE: Further description of early clinically silent lupus nephritis. Lupus. 2006, 15: 845-851.","journal-title":"Lupus"},{"key":"714_CR78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004, 15: 241-250.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR79","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/0961203310388446","volume":"20","author":"R Gupta","year":"2011","unstructured":"Gupta R, Sharma A, Bhowmik D, Gupta S, Agarwal S, Dinda A: Collapsing glomerulopathy occurring in HIV-negative patients with systemic lupus erythematosus: report of three cases and brief review of the literature. Lupus. 2011, 20: 866-870.","journal-title":"Lupus"},{"key":"714_CR80","first-page":"5","volume":"8","author":"F Mac-Moune Lai","year":"1995","unstructured":"Mac-Moune Lai F, Li EK, Tang NL, Li PK, Lui SF, Lai KN: IgA nephropathy: a rare lesion in systemic lupus erythematosus. Mod Pathol. 1995, 8: 5-10.","journal-title":"Mod Pathol"},{"key":"714_CR81","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1053\/hupa.2001.28227","volume":"32","author":"E Baranowska-Daca","year":"2001","unstructured":"Baranowska-Daca E, Choi YJ, Barrios R, Nassar G, Suki WN, Truong LD: Nonlupus nephritides in patients with systemic lupus erythematosus: a comprehensive clinicopathologic study and review of the literature. Hum Pathol. 2001, 32: 1125-1135.","journal-title":"Hum Pathol"},{"key":"714_CR82","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5414\/CNP57120","volume":"57","author":"GK Dube","year":"2002","unstructured":"Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D'Agati VD: Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002, 57: 120-126.","journal-title":"Clin Nephrol"},{"key":"714_CR83","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2004050350","volume":"16","author":"SW Kraft","year":"2005","unstructured":"Kraft SW, Schwartz MM, Korbet SM, Lewis EJ: Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005, 16: 175-179.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR84","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00296-010-1674-0","volume":"31","author":"JF de Carvalho","year":"2011","unstructured":"de Carvalho JF, da Mota LM, Bonfa E: Fatal rhabdomyolysis in systemic lupus erythematosus. Rheumatol Int. 2011, 31: 1243-1245.","journal-title":"Rheumatol Int"},{"key":"714_CR85","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/rheumatology\/keh705","volume":"44","author":"SL Li","year":"2005","unstructured":"Li SL, Liou LB, Fang JT, Tsai WP: Symptomatic renal tubular acidosis (RTA) in patients with systemic lupus erythematosus: an analysis of six cases with new association of type 4 RTA. Rheumatology (Oxford). 2005, 44: 1176-1180.","journal-title":"Rheumatology (Oxford)"},{"key":"714_CR86","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","volume":"47","author":"S Duran-Barragan","year":"2008","unstructured":"Duran-Barragan S, McGwin G, Vila LM, Reveille JD, Alarcon GS: Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus\u2013results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008, 47: 1093-1096.","journal-title":"Rheumatology (Oxford)"},{"key":"714_CR87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0961203307086503","volume":"17","author":"A Siso","year":"2008","unstructured":"Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S, Testi A, Plaza J, Sentis J, Coca A: Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008, 17: 281-288.","journal-title":"Lupus"},{"key":"714_CR88","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2010050472","volume":"21","author":"AS Bomback","year":"2010","unstructured":"Bomback AS, Appel GB: Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010, 21: 2028-2035.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR89","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002, 46: 2121-2131.","journal-title":"Arthritis Rheum"},{"key":"714_CR90","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010, 69: 61-64.","journal-title":"Ann Rheum Dis"},{"key":"714_CR91","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005, 353: 2219-2228.","journal-title":"N Engl J Med"},{"key":"714_CR92","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009, 20: 1103-1112.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR93","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.2009.412","volume":"77","author":"J Radhakrishnan","year":"2010","unstructured":"Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB: Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010, 77: 152-160.","journal-title":"Kidney Int"},{"key":"714_CR94","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","volume":"20","author":"HA Austin 3rd","year":"2009","unstructured":"Austin HA, Illei GG, Braun MJ, Balow JE: Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009, 20: 901-911.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR95","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","volume":"19","author":"H Bao","year":"2008","unstructured":"Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS: Successful treatment of class V\u2009+\u2009IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008, 19: 2001-2010.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR96","doi-asserted-by":"crossref","first-page":"s33","DOI":"10.1177\/096120330501400107","volume":"14","author":"G Contreras","year":"2005","unstructured":"Contreras G, Tozman E, Nahar N, Metz D: Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus. 2005, 14: s33-s38.","journal-title":"Lupus"},{"key":"714_CR97","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis. 2010, 69: 2083-2089.","journal-title":"Ann Rheum Dis"},{"key":"714_CR98","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011, 365: 1886-1895.","journal-title":"N Engl J Med"},{"key":"714_CR99","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","volume":"61","author":"TY Lu","year":"2009","unstructured":"Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA: A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients. Arthritis Rheum. 2009, 61: 482-487.","journal-title":"Arthritis Rheum"},{"key":"714_CR100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010, 62: 222-233.","journal-title":"Arthritis Rheum"},{"key":"714_CR101","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum. 2012, 64: 1215-1226.","journal-title":"Arthritis Rheum"},{"key":"714_CR102","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Muller-Ladner U, Konig R, Fiehn C, Burgwinkel P, Budde K, Sorensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F: Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011, 13: R75.","journal-title":"Arthritis Res Ther"},{"key":"714_CR103","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"ES Molloy","year":"2009","unstructured":"Molloy ES, Calabrese LH: Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009, 60: 3761-3765.","journal-title":"Arthritis Rheum"},{"key":"714_CR104","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","volume":"58","author":"M Petri","year":"2008","unstructured":"Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W: Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008, 58: 2453-2459.","journal-title":"Arthritis Rheum"},{"key":"714_CR105","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","volume":"61","author":"DJ Wallace","year":"2009","unstructured":"Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61: 1168-1178.","journal-title":"Arthritis Rheum"},{"key":"714_CR106","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011, 377: 721-731.","journal-title":"Lancet"},{"key":"714_CR107","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63: 3918-3930.","journal-title":"Arthritis Rheum"},{"key":"714_CR108","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","volume":"8","author":"T Dorner","year":"2006","unstructured":"Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006, 8: R74.","journal-title":"Arthritis Res Ther"},{"key":"714_CR109","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaci.2010.12.1087","volume":"127","author":"C Yildirim-Toruner","year":"2011","unstructured":"Yildirim-Toruner C, Diamond B: Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011, 127: 303-312. quiz 313\u2013304","journal-title":"J Allergy Clin Immunol"},{"key":"714_CR110","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/ar2959","volume":"12","author":"SR Dillon","year":"2010","unstructured":"Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA: B-lymphocyte stimulator\/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010, 12: R48.","journal-title":"Arthritis Res Ther"},{"key":"714_CR111","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","volume":"56","author":"M Dall'Era","year":"2007","unstructured":"Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D: Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007, 56: 4142-4150.","journal-title":"Arthritis Rheum"},{"key":"714_CR112","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/ndt\/gfr239","volume":"27","author":"GH Stummvoll","year":"2012","unstructured":"Stummvoll GH, Schmaldienst S, Smolen JS, Derfler K, Biesenbach P: Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. Nephrol Dial Transplant. 2012, 27: 618-626.","journal-title":"Nephrol Dial Transplant"},{"key":"714_CR113","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/ard.2010.148049","volume":"70","author":"GG Illei","year":"2011","unstructured":"Illei GG, Cervera R, Burt RK, Doria A, Hiepe F, Jayne D, Pavletic S, Martin T, Marmont A, Saccardi R, Voskuyl AE, Farge D: Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011, 70: 2071-2074.","journal-title":"Ann Rheum Dis"},{"key":"714_CR114","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.humimm.2005.01.022","volume":"66","author":"E Toubi","year":"2005","unstructured":"Toubi E, Kessel A, Shoenfeld Y: High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol. 2005, 66: 395-402.","journal-title":"Hum Immunol"},{"key":"714_CR115","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"WA Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999, 42: 1309-1311.","journal-title":"Arthritis Rheum"},{"key":"714_CR116","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000235941","volume":"30","author":"A Gigante","year":"2009","unstructured":"Gigante A, Gasperini ML, Cianci R, Barbano B, Giannakakis K, Di Donato D, Fuiano G, Amoroso A: Antiphospholipid antibodies and renal involvement. Am J Nephrol. 2009, 30: 405-412.","journal-title":"Am J Nephrol"},{"key":"714_CR117","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard.62.10.999","volume":"62","author":"SR Sangle","year":"2003","unstructured":"Sangle SR, D'Cruz DP, Jan W, Karim MY, Khamashta MA, Abbs IC, Hughes GR: Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis. 2003, 62: 999-1002.","journal-title":"Ann Rheum Dis"},{"key":"714_CR118","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/rheumatology\/keh490","volume":"44","author":"SR Sangle","year":"2005","unstructured":"Sangle SR, D'Cruz DP, Abbs IC, Khamashta MA, Hughes GR: Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation. Rheumatology (Oxford). 2005, 44: 372-377.","journal-title":"Rheumatology (Oxford)"},{"key":"714_CR119","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.V103507","volume":"10","author":"D Nochy","year":"1999","unstructured":"Nochy D, Daugas E, Droz D, Beaufils H, Grunfeld JP, Piette JC, Bariety J, Hill G: The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999, 10: 507-518.","journal-title":"J Am Soc Nephrol"},{"key":"714_CR120","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/ndt\/4.10.854","volume":"4","author":"D Kleinknecht","year":"1989","unstructured":"Kleinknecht D, Bobrie G, Meyer O, Noel LH, Callard P, Ramdane M: Recurrent thrombosis and renal vascular disease in patients with a lupus anticoagulant. Nephrol Dial Transplant. 1989, 4: 854-858.","journal-title":"Nephrol Dial Transplant"},{"key":"714_CR121","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.semarthrit.2006.01.001","volume":"35","author":"I Uthman","year":"2006","unstructured":"Uthman I, Khamashta M: Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum. 2006, 35: 360-367.","journal-title":"Semin Arthritis Rheum"},{"key":"714_CR122","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/art.1780270509","volume":"27","author":"G Mintz","year":"1984","unstructured":"Mintz G, Acevedo-Vazquez E, Gutierrez-Espinosa G, Avelar-Garnica F: Renal vein thrombosis and inferior vena cava thrombosis in systemic lupus erythematosus. Frequency and risk factors. Arthritis Rheum. 1984, 27: 539-544.","journal-title":"Arthritis Rheum"},{"key":"714_CR123","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.rdc.2006.05.004","volume":"32","author":"MC Amigo","year":"2006","unstructured":"Amigo MC: Kidney disease in antiphospholipid syndrome. Rheum Dis Clin North Am. 2006, 32: 509-522.","journal-title":"Rheum Dis Clin North Am"},{"key":"714_CR124","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0272-6386(03)00352-4","volume":"41","author":"F Fakhouri","year":"2003","unstructured":"Fakhouri F, Noel LH, Zuber J, Beaufils H, Martinez F, Lebon P, Papo T, Chauveau D, Bletry O, Grunfeld JP, Piette JC, Lesavre P: The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis. 2003, 41: 1205-1211.","journal-title":"Am J Kidney Dis"},{"key":"714_CR125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2369-8-7","volume":"8","author":"MM Javaid","year":"2007","unstructured":"Javaid MM, Denley H, Tagboto S: Fibrillary glomerulonephritis with small fibrils in a patient with the antiphospholipid antibody syndrome successfully treated with immunosuppressive therapy. BMC Nephrol. 2007, 8: 7.","journal-title":"BMC Nephrol"},{"key":"714_CR126","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1007\/s001470050280","volume":"13","author":"DR Wagenknecht","year":"2000","unstructured":"Wagenknecht DR, Fastenau DR, Torry RJ, Becker DG, LeFor WM, Carter CB, Haag BW, McIntyre JA: Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies. Transpl Int. 2000, 13: S78-S81.","journal-title":"Transpl Int"},{"key":"714_CR127","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00007890-199907270-00014","volume":"68","author":"DR Wagenknecht","year":"1999","unstructured":"Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA: Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation. 1999, 68: 241-246.","journal-title":"Transplantation"},{"key":"714_CR128","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/rheumatology\/keg302","volume":"42","author":"NA Dayal","year":"2003","unstructured":"Dayal NA, Isenberg DA: Endstage renal failure in primary antiphospholipid syndrome\u2013case report and review of literature. Rheumatology (Oxford). 2003, 42: 1128-1129.","journal-title":"Rheumatology (Oxford)"},{"key":"714_CR129","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1191\/0961203303lu461oa","volume":"12","author":"C Korkmaz","year":"2003","unstructured":"Korkmaz C, Kabukcuoglu S, Isiksoy S, Yalcin AU: Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy. Lupus. 2003, 12: 760-765.","journal-title":"Lupus"},{"key":"714_CR130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncprheum1017","volume":"5","author":"D Erkan","year":"2009","unstructured":"Erkan D, Lockshin MD: New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2009, 5: 160-170.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"714_CR131","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet. 2010, 376: 1094-1108.","journal-title":"Lancet"},{"key":"714_CR132","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1007\/s00296-011-2148-8","volume":"32","author":"T Kuroda","year":"2012","unstructured":"Kuroda T, Tanabe N, Kobayashi D, Wada Y, Murakami S, Nakano M, Narita I: Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis. Rheumatol Int. 2012, 32: 3155-3162.","journal-title":"Rheumatol Int"},{"key":"714_CR133","first-page":"214","volume":"28","author":"A Giordano","year":"2011","unstructured":"Giordano A, Cencioni L, Salvo DP, Berrettini M: Membranous nephropathy secondary to rheumatoid arthritis occurring during anti-TNFalpha therapy and responsive to second-line treatment with rituximab. G Ital Nefrol. 2011, 28: 214-218.","journal-title":"G Ital Nefrol"},{"key":"714_CR134","first-page":"840","volume":"27","author":"N Maruotti","year":"2009","unstructured":"Maruotti N, Corrado A, Gaudio A, Cantatore FP: Membranous nephropathy in rheumatoid arthritis: a case report. Clin Exp Rheumatol. 2009, 27: 840-842.","journal-title":"Clin Exp Rheumatol"},{"key":"714_CR135","first-page":"87","volume":"27","author":"E Honkanen","year":"1987","unstructured":"Honkanen E, Tornroth T, Pettersson E, Skrifvars B: Membranous glomerulonephritis in rheumatoid arthritis not related to gold or D-penicillamine therapy: a report of four cases and review of the literature. Clin Nephrol. 1987, 27: 87-93.","journal-title":"Clin Nephrol"},{"key":"714_CR136","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/rheumatology\/38.6.499","volume":"38","author":"R Myllykangas-Luosujarvi","year":"1999","unstructured":"Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Hakala M: Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford). 1999, 38: 499-503.","journal-title":"Rheumatology (Oxford)"},{"key":"714_CR137","first-page":"1482","volume":"33","author":"H Uda","year":"2006","unstructured":"Uda H, Yokota A, Kobayashi K, Miyake T, Fushimi H, Maeda A, Saiki O: Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol. 2006, 33: 1482-1487.","journal-title":"J Rheumatol"},{"key":"714_CR138","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/rheumatology\/36.11.1189","volume":"36","author":"M Korpela","year":"1997","unstructured":"Korpela M, Mustonen J, Teppo AM, Helin H, Pasternack A: Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol. 1997, 36: 1189-1195.","journal-title":"Br J Rheumatol"},{"key":"714_CR139","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/PL00011196","volume":"20","author":"A Gedalia","year":"2001","unstructured":"Gedalia A, Mendez EA, Craver R, Vehaskari M, Espinoza LR: Renal involvement in juvenile rheumatoid arthritis: report of two cases. Clin Rheumatol. 2001, 20: 153-156.","journal-title":"Clin Rheumatol"},{"key":"714_CR140","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1440-1797.2009.01164.x","volume":"15","author":"YS Yun","year":"2010","unstructured":"Yun YS, Song HC, Lee K, Choi EJ, Kim YS, Min JK, Kim YK: Fibrillary glomerulonephritis in rheumatoid arthritis. Nephrology (Carlton). 2010, 15: 266-267.","journal-title":"Nephrology (Carlton)"},{"key":"714_CR141","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3109\/s10165-010-0333-3","volume":"20","author":"K Kaneko","year":"2010","unstructured":"Kaneko K, Nanki T, Hosoya T, Mizoguchi F, Miyasaka N: Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis. Mod Rheumatol. 2010, 20: 632-636.","journal-title":"Mod Rheumatol"},{"key":"714_CR142","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","volume":"20","author":"MB Stokes","year":"2005","unstructured":"Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD: Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005, 20: 1400-1406.","journal-title":"Nephrol Dial Transplant"},{"key":"714_CR143","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/sarh.2000.16641","volume":"30","author":"MH Schiff","year":"2000","unstructured":"Schiff MH, Whelton A: Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2000, 30: 196-208.","journal-title":"Semin Arthritis Rheum"},{"key":"714_CR144","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10067-010-1469-4","volume":"29","author":"T Nakamura","year":"2010","unstructured":"Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M: Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2010, 29: 1395-1401.","journal-title":"Clin Rheumatol"},{"key":"714_CR145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/asheducation-2011.1.280","volume":"2011","author":"A Tyndall","year":"2011","unstructured":"Tyndall A: Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program. 2011, 2011: 280-284.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"714_CR146","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, Craig R, Hirano I, Marshall K, Ruderman E, Jovanovic B, Milanetti F, Jain S, Boyce K, Morgan A, Carr J, Barr W: Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011, 378: 498-506.","journal-title":"Lancet"},{"key":"714_CR147","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.02.015","volume":"54","author":"N Dhaun","year":"2009","unstructured":"Dhaun N, MacIntyre IM, Bellamy CO, Kluth DC: Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis. 2009, 54: 726-731.","journal-title":"Am J Kidney Dis"},{"key":"714_CR148","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/art.22634","volume":"56","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M: Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007, 56: 1985-1993.","journal-title":"Arthritis Rheum"},{"key":"714_CR149","first-page":"259","volume":"62","author":"M Vadacca","year":"2010","unstructured":"Vadacca M, Margiotta D, Sambataro D, Buzzulini F, Lo Vullo M, Rigon A, Afeltra A: BAFF\/APRIL pathway in Sjogren syndrome and systemic lupus erythematosus: relationship with chronic inflammation and disease activity. Reumatismo. 2010, 62: 259-265.","journal-title":"Reumatismo"},{"key":"714_CR150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","volume":"28","author":"M Weidenbusch","year":"2013","unstructured":"Weidenbusch M, Rommele C, Schrottle A, Anders HJ: Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013, 28: 106-111.","journal-title":"Nephrol Dial Transplant"},{"key":"714_CR151","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0961203310395802","volume":"20","author":"J Merrill","year":"2011","unstructured":"Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, Brunetta P: Assessment of flares in lupus patients enrolled in a phase II\/III study of rituximab (EXPLORER). Lupus. 2011, 20: 709-716.","journal-title":"Lupus"},{"key":"714_CR152","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","volume":"63","author":"EM Vital","year":"2011","unstructured":"Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P: B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011, 63: 3038-3047.","journal-title":"Arthritis Rheum"},{"key":"714_CR153","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011, 377: 2181-2192.","journal-title":"Lancet"},{"key":"714_CR154","first-page":"21","volume":"256","author":"AP Malaviya","year":"2012","unstructured":"Malaviya AP, Hall FC: Targeting CVD risk in chronic connective tissue disease. Practitioner. 2012, 256: 21-26.","journal-title":"Practitioner"},{"key":"714_CR155","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/0961203312447868","volume":"21","author":"M Marengo","year":"2012","unstructured":"Marengo M, Waimann C, de Achaval S, Zhang H, Garcia Gonzalez A, Richardson MN, Reveille JD, Suarez-Almazor ME: Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus. 2012, 21: 1158-1165.","journal-title":"Lupus"},{"key":"714_CR156","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/BOR.0b013e32801127c8","volume":"19","author":"L Klareskog","year":"2007","unstructured":"Klareskog L, Padyukov L, Alfredsson L: Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol. 2007, 19: 49-54.","journal-title":"Curr Opin Rheumatol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-11-95.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-11-95\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-11-95","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T05:44:36Z","timestamp":1715147076000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-11-95"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":156,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-11-95","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]},"article-number":"95"}}